Synergistic Hemoglobin Conjugate Systems
Legal Citation
Summary of the Inventive Concept
The present disclosure relates to innovative systems that integrate thiosuccinyl-crosslinked hemoglobin conjugates with cutting-edge technologies like AI, IoT, blockchain, and advanced materials to create personalized medicine solutions, optimize treatment regimens, and enhance bioavailability.
Background and Problem Solved
The original patent disclosed pegylated thiosuccinyl-crosslinked hemoglobin conjugates with improved pharmacokinetics and pharmacodynamics. However, these conjugates have limitations in terms of personalized treatment, real-time monitoring, and targeted delivery. The new inventive concept addresses these limitations by synergistically combining the conjugates with distinct technologies to create more powerful systems.
Detailed Description of the Inventive Concept
The inventive concept encompasses a range of systems, including a personalized medicine system that leverages blockchain-based data storage and AI-powered analytics to predict optimal treatment regimens. Another embodiment involves an IoT-enabled sensor system that monitors patient vital signs and uses machine learning algorithms to optimize dosing. Additionally, a pharmaceutical composition is disclosed that incorporates graphene oxide nanoparticles for enhanced bioavailability and targeted delivery. A wearable device is also envisioned for monitoring conjugate efficacy, comprising a flexible sensor array, microcontroller, and wireless communication module.
Novelty and Inventive Step
The new claims introduce non-obvious combinations of the original thiosuccinyl-crosslinked hemoglobin conjugates with AI, IoT, blockchain, and advanced materials, resulting in innovative systems that significantly improve personalized medicine, treatment optimization, and bioavailability.
Alternative Embodiments and Variations
Alternative embodiments may include the use of other advanced materials, such as nanocellulose or liposomes, to enhance bioavailability and targeted delivery. Variations of the IoT-enabled sensor system could incorporate different types of sensors, such as electrochemical or optical sensors, to monitor patient vital signs.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, precision health, and targeted therapies. The market for these systems is expected to grow substantially in the coming years, driven by the increasing demand for more effective and efficient healthcare solutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/42 |
| A | A61 | A61K47/542 |
| A | A61 | A61K47/545 |
| A | A61 | A61K47/60 |
| A | A61 | A61P9/10 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering, pharmaceutical chemistry, and drug delivery systems, with expertise in protein conjugation, polymer chemistry, and advanced medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A researcher or engineer with advanced degrees in biomedical engineering or pharmaceutical sciences, experienced in protein modification, polymer conjugation techniques, and emerging medical technologies with knowledge of AI, IoT, and advanced materials
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies and advanced materials with existing hemoglobin conjugate technologies represents a predictable extension of known drug delivery and personalized medicine approaches. The combination of blockchain, AI, and IoT with established hemoglobin conjugation techniques follows a logical progression of enhancing medical treatment through technological integration. The use of advanced materials like graphene oxide for targeted drug delivery is a well-established approach in nanomedicine that would be obvious to apply to existing hemoglobin conjugate systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,605 |
|---|---|
| Title | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
| Assignee(s) | Billion King International Limited |